Upstream Bio (NASDAQ:UPB) Downgraded by Wall Street Zen to “Strong Sell”

Wall Street Zen lowered shares of Upstream Bio (NASDAQ:UPB) from a sell rating to a strong sell rating in a research report sent to investors on Saturday morning.

A number of other brokerages also recently commented on UPB. Truist Financial reduced their target price on shares of Upstream Bio to $25.00 and set a “buy” rating on the stock in a research note on Tuesday. Mizuho cut their price target on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Upstream Bio in a report on Monday, August 3rd. JPMorgan Chase & Co. lifted their price target on shares of Upstream Bio from $8.00 to $9.00 and gave the company a “neutral” rating in a research report on Friday. Finally, HC Wainwright assumed coverage on Upstream Bio in a report on Wednesday, June 3rd. They issued a “buy” rating and a $36.00 price objective on the stock. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $29.67.

Upstream Bio Stock Up 2.3%

NASDAQ UPB opened at $7.07 on Friday. Upstream Bio has a 52 week low of $5.85 and a 52 week high of $33.68. The business’s fifty day simple moving average is $6.81 and its 200-day simple moving average is $9.90. The firm has a market cap of $387.23 million, a PE ratio of -2.44 and a beta of 1.26.

Upstream Bio (NASDAQ:UPB) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.01. Upstream Bio had a negative net margin of 4,955.67% and a negative return on equity of 48.40%. The firm had revenue of $0.77 million for the quarter, compared to analysts’ expectations of $0.56 million. Research analysts expect that Upstream Bio will post -2.87 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Man Group plc acquired a new stake in shares of Upstream Bio during the second quarter valued at about $511,000. Hsbc Holdings PLC acquired a new position in shares of Upstream Bio in the 2nd quarter worth approximately $78,000. Canada Pension Plan Investment Board acquired a new position in shares of Upstream Bio in the 2nd quarter worth approximately $80,000. Parkman Healthcare Partners LLC purchased a new position in shares of Upstream Bio during the 2nd quarter worth approximately $6,472,000. Finally, Legal & General Group Plc acquired a new stake in Upstream Bio in the 2nd quarter valued at approximately $87,000.

More Upstream Bio News

Here are the key news stories impacting Upstream Bio this week:

• Positive Sentiment: JPMorgan raised its price target for Upstream Bio (UPB) from $8 to $9 while maintaining a “Neutral” rating. The revised target implies approximately 27.3% upside from the referenced share price, providing a modest positive catalyst despite the unchanged cautious rating. Benzinga article
• Positive Sentiment: HC Wainwright retained its “Buy” rating and $36 price target, indicating substantial potential upside if Upstream Bio’s pipeline and development plans progress successfully. MarketBeat analyst coverage
• Neutral Sentiment: HC Wainwright’s revised forecasts continue to project losses, including estimated 2026 earnings of negative $3.09 per share and negative $0.79 and $0.82 per share for the third and fourth quarters, respectively. The firm’s “Buy” rating remains unchanged, but the estimates point to a lengthy path toward profitability.
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across 2026–2030: 2027 to negative $3.31 from negative $3.09, 2028 to negative $3.13 from negative $2.92, 2029 to negative $3.56 from negative $3.35, and 2030 to negative $3.84 from negative $3.42. These broader expected losses may weigh on investor sentiment and offset the benefit of JPMorgan’s target increase. MarketBeat analyst estimates

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.